Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Aging01:26

Aging

781
Aging is a complex biological phenomenon influenced by various processes that affect cellular and systemic functions. Several prominent theories attempt to explain its mechanisms, highlighting cellular limitations, oxidative damage, and hormonal changes as central factors in aging.
Cellular Clock Theory
The cellular clock theory posits that the human lifespan is closely tied to the finite capacity of cells to divide, a phenomenon governed by telomeres, which are protective caps at the ends of...
781
The Effect of Aging on Tissues01:19

The Effect of Aging on Tissues

3.6K
Several body functions deteriorate with age. The external signs of aging are easily identifiable. For example, the skin becomes dry, less elastic, and thins out, forming wrinkles. The skin of the face begins to appear looser due to a decrease in the levels of elastic and collagen fibers in the connective tissue. Additionally, melanin production in the hair follicle decreases with age, resulting in gray hair. Moreover, the senses of sight and hearing decline, so glasses and hearing aids may...
3.6K
Changes in the Appendicular Skeleton with Age01:09

Changes in the Appendicular Skeleton with Age

3.6K
The upper and lower limb initially develops as a small bulge called a limb bud, which appears on the lateral side of the early embryo. The upper limb bud appears near the end of the fourth week of development, with the lower limb bud appearing shortly after.
Initially, the limb buds consist of a core of mesenchyme covered by a layer of ectoderm. The ectoderm at the end of the limb bud thickens to form a narrow crest called the apical ectodermal ridge. This ridge stimulates the underlying...
3.6K
Genetic Screens02:46

Genetic Screens

5.8K
Genetic screens are tools used to identify genes and mutations responsible for phenotypes of interest. Genetic screens help identify individuals or a group of people at risk of developing  genetic diseases and help them with early intervention, targeted therapy, and reproductive options.
Forward genetic screens
Forward or “classical” genetic screens involve creating random mutations in an organism’s DNA using radiation, mutagens, or insertion of additional bases, which...
5.8K
Pharmacodynamics in Geriatric Patients: Effects of Age01:27

Pharmacodynamics in Geriatric Patients: Effects of Age

241
Age-related pharmacokinetic changes are extensively documented, but understanding age-related pharmacodynamic alterations is relatively limited. This knowledge gap can be partly attributed to the complexity of developing appropriate measures of drug responses compared to bioanalytical methods for determining drug concentrations.Most information regarding age-related differences in human pharmacodynamics originates from cross-sectional studies. However, these studies assume that observed mean...
241
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Absorption01:22

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Absorption

713
As individuals age, their body's physiology evolves, affecting drug pharmacokinetics. The most apparent changes occur in the gastrointestinal tract, where an increase in gastric pH, a delay in gastric emptying, and a reduction in gastrointestinal motility are observed. Remarkably, these changes do not substantially modify the absorption of orally administered drugs, particularly those absorbed via passive diffusion.Transdermal drug delivery emerges as a highly viable method for older adults due...
713

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Sex- and age- specific lung cancer incidence and mortality among Medicaid beneficiaries with and without HIV, 2001-2015.

BMC cancer·2026
Same author

Proteomic analysis of sphingolipid metabolic enzymes with risk of bladder cancer incidence and mortality in the Atherosclerosis Risk in Communities (ARIC) Study.

Cancer prevention research (Philadelphia, Pa.)·2026
Same author

Adherence to the Mediterranean diet and risk of pancreatic cancer: an analysis of 2.3 million participants in the Pooling Project of Prospective Studies of Diet and Cancer (DCPP).

European journal of epidemiology·2026
Same author

Incidence of frailty-related fracture among Medicaid beneficiaries living with HIV and cancer: A cohort study.

PloS one·2026
Same author

County-Level Structural Racism Indices and Racial Disparities in Lung Cancer Care.

JAMA network open·2026
Same author

Sensitive Period Analysis of Adulthood BMI and Cancer Risk: An Individual Participant Data Meta-Analysis of Over 720,000 Participants in the ABACus 2 Consortium.

International journal of cancer·2026

Related Experiment Video

Updated: Feb 10, 2026

Author Spotlight: Cost-Effective Transcriptomic Drug Screening - Unlocking New Targets
06:40

Author Spotlight: Cost-Effective Transcriptomic Drug Screening - Unlocking New Targets

Published on: February 23, 2024

1.8K

Cost implications of PSA screening differ by age.

Karthik Rao1, Stella Liang2, Michael Cardamone2

  • 1Johns Hopkins University School of Medicine, Baltimore, MD, USA.

BMC Urology
|May 11, 2018
PubMed
Summary
This summary is machine-generated.

Reducing prostate-specific antigen (PSA) screening, especially for older men, can significantly lower healthcare costs. Downstream costs from biopsies and treatments are major drivers, highlighting an opportunity for savings.

Keywords:
CostsProstate cancerScreening

More Related Videos

A Phenotyping Regimen for Genetically Modified Mice Used to Study Genes Implicated in Human Diseases of Aging
09:37

A Phenotyping Regimen for Genetically Modified Mice Used to Study Genes Implicated in Human Diseases of Aging

Published on: July 14, 2016

8.8K
Author Spotlight: Overcoming Challenges in Drosophila Sleep Measurement Using DAM System
05:59

Author Spotlight: Overcoming Challenges in Drosophila Sleep Measurement Using DAM System

Published on: October 20, 2023

3.2K

Related Experiment Videos

Last Updated: Feb 10, 2026

Author Spotlight: Cost-Effective Transcriptomic Drug Screening - Unlocking New Targets
06:40

Author Spotlight: Cost-Effective Transcriptomic Drug Screening - Unlocking New Targets

Published on: February 23, 2024

1.8K
A Phenotyping Regimen for Genetically Modified Mice Used to Study Genes Implicated in Human Diseases of Aging
09:37

A Phenotyping Regimen for Genetically Modified Mice Used to Study Genes Implicated in Human Diseases of Aging

Published on: July 14, 2016

8.8K
Author Spotlight: Overcoming Challenges in Drosophila Sleep Measurement Using DAM System
05:59

Author Spotlight: Overcoming Challenges in Drosophila Sleep Measurement Using DAM System

Published on: October 20, 2023

3.2K

Area of Science:

  • Health Economics
  • Urology
  • Public Health Policy

Background:

  • Guidelines recommend changes to prostate-specific antigen (PSA)-based prostate cancer screening rates.
  • The financial impact of PSA screening, including diagnosis, treatment, and adverse events, across different age groups is not well understood.
  • A cost model is needed to guide payers and health systems in evaluating screening scenarios.

Purpose of the Study:

  • To develop a cost model for PSA-based prostate cancer screening.
  • To estimate the costs associated with screening, diagnosis, treatment, and complications for various age groups.
  • To inform payers and health systems about cost considerations under different screening scenarios.

Main Methods:

  • Utilized 2013-2014 data from a large multispecialty group to determine PSA screening prevalence in men aged 50+.
  • Obtained reimbursed costs for screening, diagnosis, and treatment from a commercial health plan.
  • Developed a cost model using literature-derived transition probabilities for biopsy, diagnosis, treatment, and complications, varying screening prevalence (5-50%) and test characteristics.

Main Results:

  • PSA screening costs were 10.1%, biopsies and complications 23.3%, and treatments (for 0.3% of patients) 66.7% of total costs.
  • A 5-percentage point decrease in annual PSA screening for men aged 70+ reduced total costs by 13.8%.
  • Similar decreases in men aged 50-54 and 55-69 resulted in 2.3% and 7.3% cost reductions, respectively.

Conclusions:

  • Significant cost savings are achievable by reducing clinically unnecessary PSA-based prostate cancer screening.
  • Focusing on reducing screening for men aged 70 and older offers the greatest potential for cost reduction due to disproportionately high downstream costs.
  • The developed cost model can aid payers and health systems in financial planning related to prostate cancer screening.